Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci

被引:0
|
作者
M.-L. Muiras
Patrick Verasdonck
Florence Cottet
François Schächter
机构
[1] Fondation Jean Dausset-CEPH,
[2] 27,undefined
[3] rue Juliette Dodu,undefined
[4] F-75010 Paris,undefined
[5] France,undefined
[6] DKFZ,undefined
[7] Abteilung F0100,undefined
[8] Im Neuenheimer Feld 242,undefined
[9] D-69120 Heidelberg,undefined
[10] Germany Tel.: +49-6221-42-4613; Fax: +49-6221-42-4962; e-mail: m.muiras@DKFZ-heidelberg.de,undefined
来源
Human Genetics | 1998年 / 102卷
关键词
Glutathione; Genetic Polymorphism; Genotype Distribution; Gene Deletion; Debrisoquine;
D O I
暂无
中图分类号
学科分类号
摘要
In the present study, the possible role of genetic polymorphism of three drug-metabolizing enzymes, debrisoquine/sparteine hydroxylase (CYP2D6), glutathione S-transferase μ (GSTM1), and N-acetyltransferase (NAT2), as a putative genetic component of human longevity, was explored. A total of 817 DNA samples from a centenarian and a control (20–70 years) population was subjected to PCR-coupled RFLP methods. Subjects were genotyped for the CYP2D6*3 (A2637 deletion) and CYP2D6*4 (G1934A transition) alleles, for four mutations of NAT2 [namely, NAT2*5A (C481T), NAT2*6A (G590A), NAT2*7A (G857A), and NAT2*14A (G191A)], and for the presence or absence of GSTM1 gene deletion. No significant difference was found at these three loci between centenarian and control subjects with respect to allelic variant frequencies, genotype distributions or predicted phenotypes deduced from genotype combinations. By comparing the distribution of combined genotypes for the polymorphisms tested at the CYP2D6, NAT2, and GSTM1 loci, none of the predicted phenotypes concerning debrisoquine hydroxylase extensive-metabolizer or poor-metabolizer phenotypes, slow or fast N-acetylation capacities, and active or defective glutathione S-transferase, could be correlated with human longevity, alone or in combination.
引用
收藏
页码:526 / 532
页数:6
相关论文
共 50 条
  • [1] Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci
    Muiras, ML
    Verasdonck, P
    Cottet, F
    Schächter, F
    HUMAN GENETICS, 1998, 102 (05) : 526 - 532
  • [2] Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias
    Lemos, MC
    Cabrita, FJ
    Silva, HA
    Vivan, M
    Plácido, F
    Regateiro, FJ
    CARCINOGENESIS, 1999, 20 (07) : 1225 - 1229
  • [3] CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians
    Agundez, JAG
    Rodriguez, I
    Olivera, M
    Ladero, JM
    Garcia, MA
    Ribera, JM
    Benitez, J
    AGE AND AGEING, 1997, 26 (02) : 147 - 151
  • [4] Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
    Gaikovitch, EA
    Cascorbi, I
    Mrozikiewicz, PM
    Brockmöller, J
    Frötschl, R
    Köpke, K
    Gerloff, T
    Chernov, JN
    Roots, I
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (04) : 303 - 312
  • [5] Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
    Elena A. Gaikovitch
    Ingolf Cascorbi
    Przemyslaw M. Mrozikiewicz
    Jürgen Brockmöller
    Roland Frötschl
    Karla Köpke
    Thomas Gerloff
    Jury N. Chernov
    Ivar Roots
    European Journal of Clinical Pharmacology, 2003, 59 : 303 - 312
  • [6] Genetic polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2D6, and CYP3A4 in the Turkish population
    Semiz, A.
    Aynaci, H. K.
    Kus, E.
    Elmas, L.
    Sen, A.
    FEBS JOURNAL, 2008, 275 : 110 - 110
  • [7] Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer
    Suzuki, S
    Muroishi, Y
    Nakanishi, I
    Oda, Y
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (03) : 220 - 230
  • [8] Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer
    Shioto Suzuki
    Youko Muroishi
    Isao Nakanishi
    Yoshio Oda
    Journal of Gastroenterology, 2004, 39 : 220 - 230
  • [9] Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility
    Chen, Han-chun
    Hu, Wei-xin
    Liu, Qing-xia
    Lia, Wen-kai
    Chen, Fang-zhi
    Rao, Zhou-zhou
    Liu, Xin-fa
    Luo, Ya-ping
    Cao, Yan-fei
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2008, 17 (03) : 251 - 258
  • [10] Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes:: Analyses of mutations on NAT2 and CYP2E1 genes in a mixed Hispanic population
    Martínez, C
    Agúndez, JAG
    Olivera, M
    Llerena, A
    Ramirez, R
    Hernández, M
    Benitez, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (06) : 623 - 628